/PRNewswire/ Daewoong Pharmaceutical (KRX: 069620.KS) is pleased to announce its financial results for the third quarter of 2023. Demonstrating a consistent.
LianBio Reports Second Quarter 2023 Financial Results and Provides Corporate Update finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Mavacamten New Drug Application (NDA) under priority review with China National Medical Products Administration (NMPA)Phase 3 EXPLORER-CN trial of mavacamten in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) met primary endpointData from EXPLORER-CN trial to be presented in an oral late-breaking science session at European Society of Cardiology Congress 2023Cash, cash equivalents and marketable securities of $267.3 million with runway into the first half of 2025
ProKidney Reports Second Quarter Financial Results and Recent Corporate Highlights tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Landos Biopharma, Inc : Landos Biopharma Provides Business Update & Reports Second Quarter 2023 Results finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.